Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Clene Inc (NQ: CLNN )

4.950 +4.670 (+1667.86%)
Streaming Delayed Price Updated: 1:23 PM EDT, Jul 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 176,074
Open 5.360
Bid (Size) 4.800 (1)
Ask (Size) 4.920 (1)
Prev. Close 0.2800
Today's Range 4.590 - 5.890
52wk Range 0.2500 - 0.8499
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Prepares to Submit Briefing Book to FDA, Looks to Obtain Key Feedback Regarding NDA for CNM-Au8 in ALS
Via Investor Brand Network
Exposures Product Safety
Nasdaq Dips Over 300 Points; PepsiCo Reports Weak Sales
Via Benzinga

Performance

YTD
+1583.67%
+1583.67%
1 Month
+1045.83%
+1045.83%
3 Month
+1156.35%
+1156.35%
6 Month
+1138.43%
+1138.43%
1 Year
+511.87%
+511.87%

More News

Read More
S&P 500 Edges Higher; Indivior Shares Plummet
Via Benzinga
Topics Stocks
Exposures US Equities
Why Helen of Troy Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Crude Oil Down 1%; Soligenix Shares Surge
Via Benzinga
Exposures Fossil Fuels
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Effect 1-for-20 Reverse Stock Split
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Presents Promising Preliminary Data on CNM-Au8(R) for Rett Syndrome Treatment
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Presents Promising Preliminary Data on CNM-Au8(R) for Rett Syndrome Treatmentw
Via Investor Brand Network
Analyst Scoreboard: 5 Ratings For Clene
Via Benzinga
Delays in Diagnosing MS Highlight Need for More Awareness, Research
Via Investor Brand Network
Analyst Scoreboard: 6 Ratings For Clene
Via Benzinga
New Test Identifies Parkinson’s Before Symptoms Develop
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Reveals Important Findings From HEALEY ALS Platform Trial
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Presents New Preliminary Data Demonstrating Potential of CNM-Au8(R) as Treatment for Rett Syndrome
Via Investor Brand Network
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Presents Extended Survival Data to Support CNM-Au8® as Potential Treatment for ALS at 2024 ENCALS Meeting
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) CEO and CFO Present Corporate Updates and Future Plans at 72nd Emerging Growth Conference
Via Investor Brand Network
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Why Oracle Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) to Present at Emerging Growth Conference
Via Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present at Emerging Growth Conference
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Announces Updates on ACT-EAP for CNM-Au8(R) Compassionate Use
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Issues Update on NIH-Funded Program for CNM-Au8® in ALS
Via Investor Brand Network
Exposures Product Safety
Clene Inc. (NASDAQ: CLNN) Participates in Three Investor Conferences During May 2024, Promoting CNM-Au8(R) Neuronal Health Therapy
Via Investor Brand Network
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.